236 related articles for article (PubMed ID: 32748742)
21. A four-miRNA signature as a novel biomarker for predicting survival in endometrial cancer.
Wu YS; Lin H; Chen D; Yi Z; Zeng B; Jiang Y; Ren G
Gene; 2019 May; 697():86-93. PubMed ID: 30779946
[TBL] [Abstract][Full Text] [Related]
22. Gene Signatures and Prognostic Value of m6A RNA Methylation Regulators in Uterine Corpus Endometrial Carcinoma.
Feng Y; Yao C; Shen J; Zhou J
Discov Med; 2021; 31(164):111-120. PubMed ID: 35188885
[TBL] [Abstract][Full Text] [Related]
23. MiRNA based tumor mutation burden diagnostic and prognostic prediction models for endometrial cancer.
Lu N; Liu J; Ji C; Wang Y; Wu Z; Yuan S; Xing Y; Diao F
Bioengineered; 2021 Dec; 12(1):3603-3620. PubMed ID: 34252354
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic potential of differentially regulated microRNAs among endometriosis, endometrioid ovarian cancer, and endometrial cancer.
Kumari P; Sharma I; Saha SC; Srinivasan R; Minhas P
J Cancer Res Ther; 2021; 17(4):1003-1011. PubMed ID: 34528556
[TBL] [Abstract][Full Text] [Related]
25. Identification of an endoplasmic reticulum stress-related gene signature to predict prognosis and potential drugs of uterine corpus endometrial cancer.
Zhou P; Wu C; Ma C; Luo T; Yuan J; Zhou P; Wei Z
Math Biosci Eng; 2023 Jan; 20(2):4018-4039. PubMed ID: 36899615
[TBL] [Abstract][Full Text] [Related]
26. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
[TBL] [Abstract][Full Text] [Related]
27. Identification of m7G Methylation-Related miRNA Signature Associated with Survival and Immune Microenvironment Regulation in Uterine Corpus Endometrial Carcinoma.
Chen R; Sun K; Hou Y; Shen J; Chen J; Dong F; Wang X; Yang L; Zhang L
Biomed Res Int; 2022; 2022():8776678. PubMed ID: 36467881
[TBL] [Abstract][Full Text] [Related]
28. Multiomics profile and prognostic gene signature of m6A regulators in uterine corpus endometrial carcinoma.
Wang Y; Ren F; Song Z; Wang X; Ma X
J Cancer; 2020; 11(21):6390-6401. PubMed ID: 33033522
[TBL] [Abstract][Full Text] [Related]
29. MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis.
Zhang Y; Wang J; Fan Y; Lang F; Fu F; Liu Q
Clin Transl Oncol; 2024 Mar; 26(3):653-663. PubMed ID: 37523078
[TBL] [Abstract][Full Text] [Related]
30. miR-200a, miR-200b and miR-429 are onco-miRs that target the PTEN gene in endometrioid endometrial carcinoma.
Yoneyama K; Ishibashi O; Kawase R; Kurose K; Takeshita T
Anticancer Res; 2015 Mar; 35(3):1401-10. PubMed ID: 25750291
[TBL] [Abstract][Full Text] [Related]
31. Integrative Analysis Reveals a Nine TP53 Pathway-Related lncRNA Prognostic Signature in Endometrial Cancer.
Wang Y; Qu X; Li L; He D
Biomed Res Int; 2022; 2022():5432806. PubMed ID: 36262972
[TBL] [Abstract][Full Text] [Related]
32. Construction of prediction model for prognosis of uterine corpus endometrial carcinoma based on pyroptosis gene.
Zhang C; Bai J; Yang Y; Wang X; Liu W; Hou S; Ai Z; Xia Q; Shao L
Clin Transl Oncol; 2023 May; 25(5):1413-1424. PubMed ID: 36520385
[TBL] [Abstract][Full Text] [Related]
33. ALDH2 promotes uterine corpus endometrial carcinoma proliferation and construction of clinical survival prognostic model.
Cui YQ; Xiang Y; Meng F; Ji CH; Xiao R; Li JP; Dai ZT; Liao XH
Aging (Albany NY); 2021 Oct; 13(20):23588-23602. PubMed ID: 34670872
[TBL] [Abstract][Full Text] [Related]
34. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
35. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
36. LYL1 gene amplification predicts poor survival of patients with uterine corpus endometrial carcinoma: analysis of the Cancer genome atlas data.
Kim SI; Lee JW; Lee N; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS; Seo JS
BMC Cancer; 2018 May; 18(1):494. PubMed ID: 29716549
[TBL] [Abstract][Full Text] [Related]
37. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
38. PPP1R14B is a diagnostic prognostic marker in patients with uterine corpus endometrial carcinoma.
He K; Wang T; Huang X; Yang Z; Wang Z; Zhang S; Sui X; Jiang J; Zhao L
J Cell Mol Med; 2023 Mar; 27(6):846-863. PubMed ID: 36824011
[TBL] [Abstract][Full Text] [Related]
39. Development of an Oxidative Phosphorylation-Related and Immune Microenvironment Prognostic Signature in Uterine Corpus Endometrial Carcinoma.
Liu J; Chen T; Yang M; Zhong Z; Ni S; Yang S; Shao F; Cai L; Bai J; Yu H
Front Cell Dev Biol; 2021; 9():753004. PubMed ID: 34901000
[No Abstract] [Full Text] [Related]
40. Construction and validation of a seven-microRNA signature as a prognostic tool for lung squamous cell carcinoma.
Gan Z; Zou Q; Lin Y; Huang X; Huang Z; Chen Z; Xu Z; Lv Y
Cancer Manag Res; 2019; 11():5701-5709. PubMed ID: 31417313
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
